logo-loader
Feedback PLC

Feedback: Providing numerical back-up to radiology

TexRAD is essentially a very smart piece of software that analyses medical images to reveal features that are not always evident to the human eye

Medical Scan
Feedback owns a smart piece of software that analyses medical images to reveal features that are not always evident to the human eye

Dr Alastair Riddell’s CV reveals a high-flying career with the forerunners of what are now GE Healthcare, Johnson & Johnson and Pfizer, followed by spells guiding businesses to IPO or trade sale.

So, what attracted him to the challenge of Feedback plc (LON:FDBK), an AIM-listed medical imaging firm worth less than £9mln?

“The persistence of Tom Charlton, who would not give me any peace until I said yes,” jokes Riddell.

Now executive chairman while it searches for a new chief executive, Riddell’ says his mind was actually made up by cold hard data that underscored the potential of its main product, TexRAD.

READ: Feedback boss David Crabb leaves with immediate effec

“When I went to Cambridge and spoke to the people who do the work there it became clear there was real potential in this,” he told Proactive Investors.

“What really convinced me was a small study they’d done.”

Textural images from CT scans

TexRAD was the brainchild of Dr Balaji Ganeshan, an expert on textural analysis of images gleaned from computed tomography (CT) scans.

Distilled down to the basics, it is essentially a very smart piece of software that analyses medical images, to reveal features that are not always evident to the human eye.

In doing so, it may “in a very statistical, objective and numerical way relate the output to a prognosis for the patient”, says Riddell.

Ganeshan carried out a study of patients with liver cancer using TexRAD and the results were, in the words of the Feedback chairman, “quite remarkable”.

“It quickly dawned on me that this could be a really valuable objective tool for giving an accurate prognosis,” he adds.

Riddell was announced as chairman in June 2016, and the focus has been on getting Feedback on to a commercial footing.

Hospitals the goal

Feedback is already making money from TexRAD with sales to institutions carrying out research, but the promised land is filled with sales to hospitals.

Feedback Medical Limited has self-certified TexRAD Lung as a Class I Medical Device, in compliance with the requirements of the EU Medical Device Directive, meaning TexRAD Lung is a Medical Device CE marked for use in the EU. This will enable Feedback to lend numerical support to the very skilled, interpretative work carried out by radiologists.

Meanwhile, a tie-up with a company in Poland called Future Processing provides Feedback with the coding know-how to develop a wider product suite.

Sales of the current product, though modest, reveal there is demand from a very specialist audience in the research sphere.

It means the technology is being cited in literature by some of the leading centres for cancer research – providing a great endorsement of the TexRAD from key opinion leaders.

In fact, the technology is also starting to make an impression with businesses operating in the field.

“My view is at the moment we are far too small and far too young to be engaged in corporate discussion,” says Riddell.

“But, if we can grow sales the way I hope we can grow them, then in two or three years we might look differently at these corporate approaches.”

Cadran another option

Feedback does have another product and in April, signed a two-year agreement with Royal Papworth Hospital NHS Foundation Trust to support and maintain its Cadran picture archiving communication system (PACS), which provides decision support for scan analysis.

At 2.02p, Feedback's market valuation is £5.6mln.

 

Quick facts: Feedback PLC

Price: £0.01

Market: LSE
Market Cap: £4.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Feedback PLC named herein, including the promotion by the Company of Feedback PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Feedback PLC gearing up for big launch of its clinical...

Feedback PLC's (LON:FDBK) Tom Oakley discusses with Proactive Lonodn's Andrew Scott the upcoming commercial launch of their clinical messaging product Bleepa. Oakley expects it to change the way medical images are communicated in everyday clinical practice on mobile devices and laptops. He...

6 days, 3 hours ago

3 min read